USPTO serial 98297806
SAIL
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SAUNDERS, ANDREA DAWN
- Law office
- TMO LAW OFFICE 137
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with SAIL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Somerville, MA, US
Somerville, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CHRISTINA M. LICURSI
CHRISTINA M. LICURSI Wolf, Greenfield & Sacks, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in gene therapy; biological and pharmaceutical preparations, both comprised of therapeutic nucleic acids, namely RNA, for the treatment and prevention of genetic diseases and disorders, genomic diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders; Therapeutic preparations to modulate metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use; therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolism; none of the foregoing for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity | ACTIVE | — |
| 042 | Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; research and development in the field of computational biology, biotechnology and pharmaceuticals; none of the foregoing related to the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 30, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 29, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 29, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 29, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 2, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 21, 2025 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Oct 21, 2025 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Oct 21, 2025 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Dec 4, 2024 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Dec 4, 2024 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| Nov 5, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 5, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 16, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 26, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 25, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 25, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 25, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 2, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 28, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 4, 2023 | NWAP | NEW APPLICATION ENTERED | — |